271 reports of this reaction
1.8% of all ROMOSOZUMAB AQQG reports
#13 most reported adverse reaction
INJECTION SITE SWELLING is the #13 most commonly reported adverse reaction for ROMOSOZUMAB AQQG, manufactured by Amgen, Inc. There are 271 FDA adverse event reports linking ROMOSOZUMAB AQQG to INJECTION SITE SWELLING. This represents approximately 1.8% of all 15,195 adverse event reports for this drug.
Patients taking ROMOSOZUMAB AQQG who experience injection site swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE SWELLING is a less commonly reported adverse event for ROMOSOZUMAB AQQG, but still significant enough to appear in the safety profile.
In addition to injection site swelling, the following adverse reactions have been reported for ROMOSOZUMAB AQQG:
The following drugs have also been linked to injection site swelling in FDA adverse event reports:
INJECTION SITE SWELLING has been reported as an adverse event in 271 FDA reports for ROMOSOZUMAB AQQG. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE SWELLING accounts for approximately 1.8% of all adverse event reports for ROMOSOZUMAB AQQG, making it a notable side effect.
If you experience injection site swelling while taking ROMOSOZUMAB AQQG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.